A deterministic history of records added to PeptideScanner and preserved profile or record revisions connected through the reviewed Semaglutide identity.
ClinicalTrials.gov posted a newer version of NCT06015893, with a registry update date of 2026-11-16. This version reports that observation; the earlier retained observation remains available as version 1.
PeptideScanner change date
November 16, 2026
Cited source date
November 16, 2026
Evidence lane
Clinical trials
Summary
Before
PeptideScanner retained ClinicalTrials.gov record NCT06015893 at 2026-08-13T05:52:27.015Z. Its registry update date was 2026-08-03, and PeptideScanner's reviewed identity mapping was semaglutide.
After
PeptideScanner retained ClinicalTrials.gov record NCT06015893 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was semaglutide.
1. PeptideScanner retained ClinicalTrials.gov record NCT06015893 at 2026-08-13T05:52:27.015Z. Its registry update date was 2026-08-03, and PeptideScanner's reviewed identity mapping was semaglutide. [sources: ctg-observation-nct06015893-2026-08-03-32ebc1c71794]
2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct06015893-2026-08-03-32ebc1c71794]
After
1. PeptideScanner retained ClinicalTrials.gov record NCT06015893 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was semaglutide. [sources: ctg-observation-nct06015893-2026-08-03-32ebc1c71794-r2]
2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct06015893-2026-08-03-32ebc1c71794-r2]
PubMed revised the bibliographic metadata of PMID 42196730, with a metadata revision date of 2026-11-01. This version reports that observation; the earlier retained observation remains available as version 1.
PeptideScanner change date
November 16, 2026
Cited source date
November 1, 2026
Evidence lane
Literature metadata
Summary
Before
PubMed lists PMID 42196730 in International journal of environmental research and public health as Journal Article, with publication-date metadata of 2026-05-12 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
After
PubMed lists PMID 42196730 in International journal of environmental research and public health as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-05-12 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
1. PubMed lists PMID 42196730 in International journal of environmental research and public health as Journal Article, with publication-date metadata of 2026-05-12 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. [sources: pubmed-observation-pmid-42196730-2026-07-17-4b8a02c2889c]
2. This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. [sources: pubmed-observation-pmid-42196730-2026-07-17-4b8a02c2889c]
After
1. PubMed lists PMID 42196730 in International journal of environmental research and public health as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-05-12 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. [sources: pubmed-observation-pmid-42196730-2026-07-17-4b8a02c2889c-r2]
2. This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. [sources: pubmed-observation-pmid-42196730-2026-07-17-4b8a02c2889c-r2]
PubMed revised the bibliographic metadata of PMID 42432542, with a metadata revision date of 2026-10-09. This version reports that observation; the earlier retained observation remains available as version 1.
PeptideScanner change date
November 16, 2026
Cited source date
October 9, 2026
Evidence lane
Literature metadata
Summary
Before
PubMed lists PMID 42432542 in BMC ophthalmology as Journal Article, with publication-date metadata of 2026-07-10 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
After
PubMed lists PMID 42432542 in BMC ophthalmology as Journal Article, Case Reports, with publication-date metadata of 2026-07-10 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
1. PubMed lists PMID 42432542 in BMC ophthalmology as Journal Article, with publication-date metadata of 2026-07-10 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. [sources: pubmed-observation-pmid-42432542-2026-07-10-5adc8b896313]
2. This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. [sources: pubmed-observation-pmid-42432542-2026-07-10-5adc8b896313]
After
1. PubMed lists PMID 42432542 in BMC ophthalmology as Journal Article, Case Reports, with publication-date metadata of 2026-07-10 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. [sources: pubmed-observation-pmid-42432542-2026-07-10-5adc8b896313-r2]
2. This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. [sources: pubmed-observation-pmid-42432542-2026-07-10-5adc8b896313-r2]
PubMed revised the bibliographic metadata of PMID 42469146, with a metadata revision date of 2026-11-03. This version reports that observation; the earlier retained observation remains available as version 1.
PeptideScanner change date
November 16, 2026
Cited source date
November 3, 2026
Evidence lane
Literature metadata
Summary
Before
PubMed lists PMID 42469146 in Nutrition, metabolism, and cardiovascular diseases : NMCD as Journal Article, with publication-date metadata of 2026-07-16 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
After
PubMed lists PMID 42469146 in Nutrition, metabolism, and cardiovascular diseases : NMCD as Journal Article, Review, Consensus Statement, with publication-date metadata of 2026-07-16 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
1. PubMed lists PMID 42469146 in Nutrition, metabolism, and cardiovascular diseases : NMCD as Journal Article, with publication-date metadata of 2026-07-16 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. [sources: pubmed-observation-pmid-42469146-2026-07-17-b145ec90ac55]
2. This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. [sources: pubmed-observation-pmid-42469146-2026-07-17-b145ec90ac55]
After
1. PubMed lists PMID 42469146 in Nutrition, metabolism, and cardiovascular diseases : NMCD as Journal Article, Review, Consensus Statement, with publication-date metadata of 2026-07-16 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. [sources: pubmed-observation-pmid-42469146-2026-07-17-b145ec90ac55-r2]
2. This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. [sources: pubmed-observation-pmid-42469146-2026-07-17-b145ec90ac55-r2]
ClinicalTrials.gov posted a newer version of NCT06299098, with a registry update date of 2026-11-12. This version reports that observation; the earlier retained observation remains available as version 1.
PeptideScanner change date
November 15, 2026
Cited source date
November 12, 2026
Evidence lane
Clinical trials
Summary
Before
PeptideScanner retained ClinicalTrials.gov record NCT06299098 at 2026-08-10T18:10:03.940Z. Its registry update date was 2026-07-21, and PeptideScanner's reviewed identity mapping was semaglutide.
After
PeptideScanner retained ClinicalTrials.gov record NCT06299098 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was semaglutide.
1. PeptideScanner retained ClinicalTrials.gov record NCT06299098 at 2026-08-10T18:10:03.940Z. Its registry update date was 2026-07-21, and PeptideScanner's reviewed identity mapping was semaglutide. [sources: ctg-observation-nct06299098-2026-07-21-3f43d1be33b9]
2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct06299098-2026-07-21-3f43d1be33b9]
After
1. PeptideScanner retained ClinicalTrials.gov record NCT06299098 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was semaglutide. [sources: ctg-observation-nct06299098-2026-07-21-3f43d1be33b9-r2]
2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct06299098-2026-07-21-3f43d1be33b9-r2]
We added a plain-language reader guide with cited answers, re-checked the Wegovy label and the Drugs@FDA approval records, and added FDA’s current page on unapproved GLP-1 drugs (content current as of October 1, 2026) and its April 2026 503B proposal. An August 2026 Ozempic supplement changed carton labeling only and is not reflected.
PeptideScanner change date
November 14, 2026
Evidence lane
Profile
Status
Before
U.S. label record
After
FDA-approved as Ozempic, Rybelsus and Wegovy
Profile summary
Before
A GLP-1 receptor agonist. This profile cites a Wegovy label and an FDA notice.
After
A GLP-1 receptor agonist approved by FDA as Ozempic, Rybelsus and Wegovy. Its approved uses rest on large randomized trials described in the label.
Evidence note
Before
The cited DailyMed label identifies Semaglutide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.
After
The Wegovy label covers weight reduction, cardiovascular risk reduction in adults with established cardiovascular disease and obesity or overweight, and MASH under accelerated approval, and carries a boxed warning about thyroid C-cell tumors in rodents. FDA says compounded and other unapproved semaglutide products are not FDA-approved.
U.S. National Library of Medicine [sources: dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19]
After
U.S. National Library of Medicine [sources: dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19]; U.S. Food and Drug Administration [sources: fda-drugs-nda209637-2017-12-05-0b9e82eeabee, fda-unapproved-glp1-concerns-2026-r2]
Showing the latest 100 additions by PeptideScanner publication date; the complete connected record set remains available on the cross-source timeline. Most recent addition: November 14, 2026.
PeptideScanner retained ClinicalTrials.gov record NCT03596450 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-30, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT04916470 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-02, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT05254314 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-01, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT05714683 at 2026-11-14T22:51:22.481Z. Its registry update date was 2026-09-18, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT06045221 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-15, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT06058585 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-05, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT06706284 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-05, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT06715514 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-16, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT06738979 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-25, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT06778967 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-10, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT06908694 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-14, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT06977438 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-20, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07064486 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-13, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07112872 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07284979 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-06, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07400107 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-10, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07415954 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-11, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07511543 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-24, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07547878 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-13, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07564414 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-30, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07639021 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-16, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07642635 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07668388 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-07, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07743983 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-13, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07770841 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-09, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07812597 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-10, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07836140 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-23, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07845578 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-29, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07849348 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-30, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07850765 at 2026-11-14T22:51:22.481Z. Its registry update date was 2026-09-30, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07855133 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-16, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07858331 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-05, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07871799 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-13, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07879612 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-19, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07881770 at 2026-11-14T22:51:22.481Z. Its registry update date was 2026-10-19, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07891156 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-23, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07900438 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-28, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07909889 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-02, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07911046 at 2026-11-14T22:51:22.481Z. Its registry update date was 2026-11-02, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07931573 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07931599 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07935200 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-13, and PeptideScanner's reviewed identity mapping was semaglutide.
PubMed lists PMID 42722400 in BMJ (Clinical research ed.) as Journal Article, with publication-date metadata of 2026-09-10 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 42754946 in Acta psychiatrica Scandinavica as Letter, with publication-date metadata of 2026-09-17 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 42769283 in Cureus as Editorial, with publication-date metadata of 2026-08-21 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 42785112 in The journal of prevention of Alzheimer's disease as Journal Article, Review, with publication-date metadata of 2026-09-24 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 42823892 in Drug testing and analysis as Journal Article, with publication-date metadata of 2026-10-02 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 42862749 in Cardiology as Journal Article, with publication-date metadata of 2026-10-12 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 42901618 in BMJ (Clinical research ed.) as Journal Article, with publication-date metadata of 2026-10-20 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 42946801 in Journal of gastroenterology as Editorial, with publication-date metadata of 2026-10-27 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 42977490 in Archives of disease in childhood as Journal Article, with publication-date metadata of 2026-11-03 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 42999829 in Cureus as Case Reports, Journal Article, with publication-date metadata of 2026-10-08 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 43011941 in Indian journal of psychiatry as Letter, with publication-date metadata of 2026-10-21 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT03811561 at 2026-09-09T19:17:17.089Z. Its registry update date was 2026-09-09, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07662213 at 2026-09-09T19:17:17.121Z. Its registry update date was 2026-09-09, and PeptideScanner's reviewed identity mapping was semaglutide.
PubMed lists PMID 40536021 in Qualitative health research as Journal Article, with publication-date metadata of 2025-06-19 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 42703141 in JPMA. The Journal of the Pakistan Medical Association as Journal Article, with publication-date metadata of 2026-08 (month precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 42703150 in JPMA. The Journal of the Pakistan Medical Association as Journal Article, with publication-date metadata of 2026-08 (month precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
FDA's dated enforcement report D-0536-2021 lists Class II and source status Terminated for Cardinal Health Inc. PeptideScanner connects the report to reviewed application NDA213051 through exact openFDA application-number annotations.
DailyMed lists Structured Product Labeling version 1 for the reviewed Semaglutide label family with a published date of 2021-06-07. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 10 for the reviewed Semaglutide label family with a published date of 2024-12-12. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 11 for the reviewed Semaglutide label family with a published date of 2025-08-29. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 12 for the reviewed Semaglutide label family with a published date of 2025-11-17. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 13 for the reviewed Semaglutide label family with a published date of 2025-12-05. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 14 for the reviewed Semaglutide label family with a published date of 2026-01-06. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 15 for the reviewed Semaglutide label family with a published date of 2026-02-12. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 16 for the reviewed Semaglutide label family with a published date of 2026-03-05. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 17 for the reviewed Semaglutide label family with a published date of 2026-04-02. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 18 for the reviewed Semaglutide label family with a published date of 2026-05-22. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 19 for the reviewed Semaglutide label family with a published date of 2026-06-30. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 2 for the reviewed Semaglutide label family with a published date of 2022-11-11. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 3 for the reviewed Semaglutide label family with a published date of 2023-01-09. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 4 for the reviewed Semaglutide label family with a published date of 2023-02-27. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 5 for the reviewed Semaglutide label family with a published date of 2023-03-08. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 6 for the reviewed Semaglutide label family with a published date of 2023-08-01. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 7 for the reviewed Semaglutide label family with a published date of 2024-03-18. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 8 for the reviewed Semaglutide label family with a published date of 2024-04-12. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 9 for the reviewed Semaglutide label family with a published date of 2024-11-15. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The Federal Register published notice 2017-21176, attributed to FDA and its parent HHS department, on 2017-10-03. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Semaglutide.
The Federal Register published notice 2019-25850, attributed to FDA and its parent HHS department, on 2019-11-29. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; OZEMPIC,” and PeptideScanner's exact reviewed identity mapping connects the document to Semaglutide.
The Federal Register published notice 2020-04320, attributed to FDA and its parent HHS department, on 2020-03-03. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Liraglutide and Semaglutide.
The Federal Register published notice 2021-18072, attributed to FDA and its parent HHS department, on 2021-08-23. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide and Semaglutide.
The Federal Register published notice 2023-25485, attributed to FDA and its parent HHS department, on 2023-11-17. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Semaglutide.
The Federal Register published notice 2025-19345, attributed to FDA and its parent HHS department, on 2025-10-02. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Semaglutide.
The Federal Register published notice 2025-22131, attributed to FDA and its parent HHS department, on 2025-12-05. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Glucagon, Liraglutide, Semaglutide, Teriparatide, Tirzepatide and Vosoritide.
The Federal Register published notice 2026-02786, attributed to FDA and its parent HHS department, on 2026-02-12. Its official title is “Jeremy Spencer Brown: Final Debarment Order,” and PeptideScanner's exact reviewed identity mapping connects the document to Semaglutide.
The Federal Register published notice 2026-03963, attributed to FDA and its parent HHS department, on 2026-02-27. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Octreotide and Semaglutide.
The Federal Register published notice 2026-08435, attributed to FDA and its parent HHS department, on 2026-04-30. Its official title is “Determination That OZEMPIC (Semaglutide) Solution, 2 Milligrams Per 1.5 Milliliters Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Semaglutide.
The Federal Register published notice 2026-08552, attributed to FDA and its parent HHS department, on 2026-05-01. Its official title is “List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act,” and PeptideScanner's exact reviewed identity mapping connects the document to Glucagon, Liraglutide, Semaglutide and Tirzepatide.
The Federal Register published notice 2026-12937, attributed to FDA and its parent HHS department, on 2026-06-26. Its official title is “List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Extension of Comment Period,” and PeptideScanner's exact reviewed identity mapping connects the document to Liraglutide, Semaglutide and Tirzepatide.
The Federal Register published notice 2026-15285, attributed to FDA and its parent HHS department, on 2026-07-29. Its official title is “Product-Specific Guidances; Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Glucagon, Liraglutide, Semaglutide, Teriparatide, Tirzepatide and Vosoritide.
PubMed lists PMID 40850442 in Journal of controlled release : official journal of the Controlled Release Society as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2025-08-22 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 41524543 in Expert review of pharmacoeconomics & outcomes research as Journal Article, Observational Study, with publication-date metadata of 2026-01-12 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 42364353 in Medicina clinica as Letter, with publication-date metadata of 2026-06-27 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 42602345 in Canadian journal of kidney health and disease as Journal Article, with publication-date metadata of 2026-08-13 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT03884075 at 2026-08-13T05:52:27.026Z. Its registry update date was 2026-08-10, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07087795 at 2026-08-13T16:32:13.881Z. Its registry update date was 2026-08-13, and PeptideScanner's reviewed identity mapping was semaglutide.
The official Drugs@FDA dataset lists original submission 1 for NDA 209637 with status AP dated 2017-12-05, and names semaglutide among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for NDA 213051 with status AP dated 2019-09-20, and names semaglutide among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for NDA 213182 with status AP dated 2020-01-16, and names semaglutide among the application record's active ingredients.